MIX OFFER 1: Pick any one, two or three oncology reports for free when you choose to buy one report from below categories
- A 7,600 USD report gives one free oncology report (Minimum value: 2,468 USD)
- A 11,400 USD report gives two free oncology report (Minimum value: 4,936 USD)
- A 15,200 USD report gives three free oncology report (Minimum value: 7,404 USD) |
| Promotion code: MIX108 |
|
| Valid until: DEC 31st, 2008 |
|
| Please Download order sheet to take advantage of listed offers and fax it back to us at +46-8-56849191. List the report you would like to buy and follow it by the free report(s). |
|
|
|
|
|
|
| FREE Oncology reports to go with below report categories |
| Release Date |
Title |
Price (USD) |
| 14-Oct-08 |
Currently Druggable in Melanoma: A Drug Target Competitive Analysis |
$3 100 |
| 8-Sep-08 |
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis |
$3 100 |
| 12-Aug-08 |
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis |
$3 100 |
| 3-Jun-08 |
Cancer Antibodies: Competitive Positioning for Success |
$3 100 |
| 19-May-08 |
Cancer Vaccines: Aim and Shoot |
$3 100 |
| 1-Apr-08 |
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics |
$3 600 |
| 17-Mar-08 |
Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology |
$3 850 |
| 6-Feb-08 |
The Drug Target Atlas of Apoptopic Drugs in Oncology |
$3 850 |
| 5-Nov-07 |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology |
$3 556 |
| 14-Sep-07 |
Decoding Big Pharmas R&D Strategy in Oncology |
$3 430 |
| 19-Jul-07 |
Melanoma - Targeted Therapeutics |
$2 708 |
| 12-Jun-07 |
Antibody Drug Target Atlas in Oncology |
$3 269 |
| 30-Apr-07 |
Global Cancer Focus Company Directory |
$2 785 |
| 26-Apr-07 |
Targeted Therapeutics in Non-Small Cell Lung Cancer |
$2 785 |
| 27-Mar-07 |
Global Pipeline Review & Analysis of Hematological Malignancies |
$3 100 |
| 28-Feb-07 |
Breast Cancer - Therapeutic And Competitive Insights |
$2 468 |
| 5-Jan-07 |
Prostate Cancer - A Therapeutic & Competitive Insight |
$2 468 |
| 19-Dec-06 |
Competitive Outlook on Apoptosis in Oncology |
$2 468 |
| 9-Oct-06 |
Outlook on Antiangiogenesis and Vascular Targeting in Oncology |
$2 468 |
| 6-Oct-06 |
Leukemia - A Therapeutic & Competitive Insight |
$2 468 |
| 3-Aug-06 |
Competitive Outlook on Non-Antibody Based Cancer Vaccines |
$2 468 |
| 29-May-06 |
Lymphoma - A Therapeutic & Competitive Insight |
$2 468 |
| 14-Mar-06 |
Current and Future Therapies for Lung Cancer |
$2 468 |
| 20-Feb-06 |
Strategic Outlook on Protein Kinase Inhibitors in Oncology |
$2 468 |
|
|
|
| ONE free oncology report to go with below reports (Minimum value: 2,468 USD) |
| Release Date |
Title |
Price (USD) |
| 21-Aug-08 |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape |
$7 600 |
| 7-Aug-08 |
Biosimilars Series: Stakeholder Analysis |
$7 600 |
| 15-Jul-08 |
Optimizing Brand Lifecycle Mngmt In Growing Generic Competition |
$7 600 |
| 2-Jul-08 |
Stakeholder Opinions: Novel Therapeutic Approaches in Cardiovascular Medicine |
$7 600 |
| 6-Jun-08 |
Monoclonal Antibodies Report: 2008 Update |
$7 600 |
| 12-Mar-08 |
Emerging pharmaceutical markets Argentina and Mexico |
$7 600 |
| 25-Dec-07 |
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape |
$7 600 |
| 23-Oct-07 |
Analysis of the Pharmaceutical Market to 2012 |
$7 600 |
| 26-Sep-07 |
Monoclonal Antibodies Report Part II: Companies - Holding mAbs |
$7 600 |
| 2-Jul-07 |
Disease Management and Drug Adherence |
$7 600 |
| 9-Apr-07 |
Generic Series: Benchmarking Patent Expiries |
$7 600 |
|
|
|
| TWO free oncology reports to go with below reports (Minimum value: 4,936 USD) |
| Release Date |
Title |
Price (USD) |
| 25-Sep-08 |
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types |
$11 400 |
| 22-Jul-08 |
Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid |
$11 400 |
| 10-Jul-08 |
Pipeline Insight: Insulin antidiabetics |
$11 400 |
| 28-May-08 |
Pipeline Insight: Non-insulin antidiabetics |
$11 400 |
| 23-May-08 |
Pipeline Insight: Acute Stroke: Commercial risk offsets high unmet need |
$11 400 |
| 17-Apr-08 |
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates |
$11 400 |
| 17-Apr-08 |
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements |
$11 400 |
| 17-Apr-08 |
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine? |
$11 400 |
| 26-Sep-07 |
Pipeline Insight: Neuropathic Pain - Emerging drugs fail... |
$11 400 |
| 15-Aug-07 |
Pipeline Insight: Heart failure |
$11 400 |
| 11-Jul-07 |
Pipeline Insight: Upper GI Disorders - Generics will limit... |
$11 400 |
| 17-Apr-07 |
Pipeline Insight: Disease Modification in Rheumatoid Arthritis |
$11 400 |
| 12-Apr-07 |
Pipeline Insight:Insomnia-Targeting the sleep maintenance market |
$11 400 |
| 9-Apr-07 |
Pipeline Insight: Antithrombotics |
$11 400 |
| 9-Apr-07 |
Pipeline Insight: Dyslipidemia |
$11 400 |
| 30-Mar-07 |
Pipeline Insight: Hematological Malignancies |
$11 400 |
| 30-Mar-07 |
Pipeline Insight: Multiple Sclerosis - The oral revolution |
$11 400 |
| 30-Mar-07 |
Pipeline Insight: Osteoporosis |
$11 400 |
| 22-Mar-07 |
Pipeline Insight: Depression |
$11 400 |
|
|
|
| THREE free oncology reports to go with below reports (Minimum value: 7,404 USD) |
| Release Date |
Title |
Price (USD) |
| 8-Sep-08 |
Commercial Insight: Inflammatory Bowel Disease |
$15 200 |
| 8-Sep-08 |
Forecast Insight: Parkinsons Disease |
$15 200 |
| 27-Aug-08 |
Forecast Insight: Dyslipidemia |
$15 200 |
| 26-Aug-08 |
Commercial Insight: Select herpes viruses& human papilloma virus |
$15 200 |
| 26-Aug-08 |
Forecast Insight: Antidiabetics |
$15 200 |
| 21-Aug-08 |
Commercial Insight: Antihormonal Therapy Cancer Brands |
$15 200 |
| 21-Aug-08 |
Commercial Insight: Top 20 Therapy Cancer Brands |
$15 200 |
| 20-Aug-08 |
Commercial Insight: HIV - The battle for market... |
$15 200 |
| 20-Aug-08 |
Forecast Insight: Insomnia Orexin and serotonin receptor... |
$15 200 |
| 20-Aug-08 |
Forecast Insight: Multiple Sclerosis |
$15 200 |
| 7-Aug-08 |
Forecast Insight: Asthma/COPD |
$15 200 |
| 24-Jul-08 |
Forecast Insight: Antihypertensives |
$15 200 |
| 18-Jul-08 |
Commercial Insight: Cytotoxic Therapy Cancer Brands |
$15 200 |
| 18-Jul-08 |
Commercial Insight: Targeted Therapy Cancer Brands |
$15 200 |
| 2-Jul-08 |
Commercial & Pipeline Insight: Vaccines for Adults & the Elderly |
$15 200 |
| 2-Jul-08 |
Commercial and Pipeline Insight: Fibromyalgia |
$15 200 |
| 1-Jul-08 |
Stakeholder Insight: Asthma - Over-prescribing is common... |
$15 200 |
| 16-Jun-08 |
Pipeline and Commercial Insight: Neuropathic Pain |
$15 200 |
| 23-May-08 |
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses |
$15 200 |
| 17-Apr-08 |
Commercial and Pipeline Insight: HRT for Menopausal Symptoms |
$15 200 |
| 17-Apr-08 |
Commercial Insight: CNS Market Overview |
$15 200 |
| 10-Apr-08 |
Commercial and Pipeline Insight: ADHD |
$15 200 |
| 26-Mar-08 |
Commercial and Pipeline Insight: Opioids |
$15 200 |
| 26-Mar-08 |
Pipeline and Commercial Insight: Alzheimers Disease |
$15 200 |
| 9-Jan-08 |
Emerging markets series:Benchmarking key countries BRIC & Turkey |
$15 200 |
| 31-Oct-07 |
Commercial and Pipeline Insight: Hepatitis B |
$15 200 |
| 24-Oct-07 |
Commercial Insight: Cardiovascular market overview |
$15 200 |
| 23-Oct-07 |
Pipeline Insight: Molecular Targeted Cancer Therapies |
$15 200 |
| 19-Oct-07 |
Stakeholder Insight: Acute Stroke - TPA spurs infrastructure |
$15 200 |
| 15-Oct-07 |
Stakeholder Insight: Renal Cancer |
$15 200 |
| 12-Oct-07 |
Commercial Insight: Antithrombotics - Market expands... |
$15 200 |
| 28-Sep-07 |
Pipeline and Commercial Insight: Parkinson's Disease |
$15 200 |
| 28-Sep-07 |
Pipeline Insight: Cancer Overview - Increasing diversity |
$15 200 |
| 26-Sep-07 |
Commercial Insight: Epilepsy - Companies committed to the cause |
$15 200 |
| 26-Sep-07 |
Commercial Insight: Migraine - Opportunities will exist |
$15 200 |
| 24-Aug-07 |
Commercial & Pipeline Insight: Hospital Antibacterials |
$15 200 |
| 23-Aug-07 |
Commercial Insight: Antidiabetics |
$15 200 |
| 22-Aug-07 |
Launch Strategies - Analyzing Market Trends & Regulatory Impacts |
$15 200 |
| 9-Aug-07 |
R&D Strategies: Incremental improvements and paradigm shifts |
$15 200 |
| 23-Jul-07 |
Pipeline and Commercial Insight: Pediatric & Adolescent Vaccines |
$15 200 |
| 11-Jul-07 |
Commercial Insight: Antidyslipidemics |
$15 200 |
| 11-Jul-07 |
Commercial Insight: Asthma & COPD - Combination products... |
$15 200 |
| 11-Jul-07 |
Commercial Insight: HIV - Reshaping Treatment Paradigms |
$15 200 |
| 2-Jul-07 |
Commercial Insight: Top 20 Cancer Therapy Brands |
$15 200 |
| 15-Jun-07 |
Pipeline/Commercial Insight: Supportive Care in Oncology |
$15 200 |
| 6-Apr-07 |
Pipeline and Commercial Insight: Influenza Vaccines |
$15 200 |
| MIX OFFER 2: Buy One Get One Free |
| Promotion code: MIX208 |
|
| Valid until: DEC 31st, 2008 |
|
| Please Download order sheet to take advantage of listed offers and fax it back to us at +46-8-56849191. List the report you would like to buy and follow it by the free report(s). |
|
|
|
| Release Date |
Title |
Price (USD) |
| 1-Oct-08 |
Biotech M&A Strategies: Deal assessments, trends & future prospects |
$3 835 |
| 1-Jun-08 |
Contract Manufacturing Strategies: Market developments, technology transfer and key success factors |
$3 835 |
| 1-Apr-08 |
Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response |
$3 835 |
| 1-Mar-08 |
Impact of Pharmacogenomics on Public Healthcare Policy: Educating patients, payors and healthcare providers |
$3 835 |
| 1-Aug-08 |
Innovations and Pipelines for Respiratory Disorders: Niche markets, new products and future developments |
$3 835 |
| 1-Jun-08 |
Innovations in The Management of Diabetes: Next generation treatments and market dynamics |
$3 835 |
| 1-Jan-08 |
Launching Combination Products: Brand extension and franchise development strategies |
$3 835 |
| 1-Jun-08 |
Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments |
$3 835 |
| 1-Jul-08 |
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment |
$3 835 |
| 1-Sep-08 |
Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships |
$3 835 |
| 1-Aug-08 |
The Anti-Infectives Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities |
$3 835 |
| 1-Jan-08 |
The Cancer Market Outlook to 2012 |
$3 835 |
| 1-Feb-08 |
The Cardiovascular Disorders Market Outlook to 2012 |
$3 835 |
| 1-Sep-08 |
The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities |
$3 835 |
| 1-Oct-08 |
The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities |
$3 835 |
| 1-Mar-08 |
The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players |
$3 835 |
| 1-Nov-08 |
The Promotional Landscape in US and Europe: Benchmarking promotional ROI and optimizing detailing and journal spend |
$3 835 |
| 1-Jul-08 |
The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses |
$3 835 |
| 1-Nov-08 |
The Top Ten Specialty Pharmaceutical Companies: Positioning, performance and SWOT analyses |
$3 835 |
| 1-Jul-08 |
Valuing Pharmaceutical Innovation: Pricing and reimbursement for innovative therapies |
$3 835 |
